Navigation Links
MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis
Date:7/24/2008

NEW YORK, July 24 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM) today announced results of a Phase 2 clinical trial involving 37 patients who completed a 48-week, U.S. multi-center, open-label efficacy and safety study of EcoNail, a topical antifungal lacquer for the treatment of onychomycosis (nail fungus). The composite primary efficacy endpoint of the trial was "complete cure" defined as negative mycology (negative fungal culture and negative KOH) and clear nail (as determined by expert panel review of clinical photographs). EcoNail is the company's patented, topically-applied lacquer which contains the antifungal econazole and MacroChem's enhancer SEPA(R).

A protocol-mandated, external expert panel assessed clinical photographs of 37 onychomycosis patients who completed 48 weeks of EcoNail treatment. The panel observed that 24 patients (65%) showed evidence of clinical improvement, defined in the protocol as an increase in uninvolved (clear) nail area. While none of the 37 patients reached all criteria of the composite primary endpoint, the consensus judgment of the panel was that 15 of 37 patients (41%) demonstrated significant (greater than or equal to 25%) clinical improvement. All patients had fungal culture-proven nail infections at entry, but after 48 weeks of once-daily treatment with EcoNail, 100% of patients had cultures that were negative for dermatophyte growth. Eight of the 37 patients (22%) achieved the secondary endpoint of negative mycology (negative fugal culture plus negative KOH evaluation) at 48 weeks. The panel observed no signs of local irritation related to the once-daily EcoNail treatment. During the trial, no patient required interruption of dosing due to local intolerability. Through 56 weeks of observation, no cutaneous adverse events were attributed by the investigators to EcoNail.

The laboratory of Boni Elewski, MD, Professor of Dermatology at the University of Alabama-Birmingham, perf
'/>"/>

SOURCE MacroChem Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
4. FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
5. InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
6. Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
9. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
10. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
11. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ... very important aspects in today,s growth in ...
(Date:1/14/2014)... FRAMINGHAM, Mass. , Jan. 14, 2014 /PRNewswire/ ... HTWR ), a leading innovator of less ... the treatment of advanced heart failure, today announced ... of 2013 will be approximately $53 million, bringing ... "Our full-year revenue growth of 87% ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic ... LLC ("GMH"), announced today that it acquired Progressive Home Medical ... on January 7, 2014. The terms of the acquisition were ... durable medical equipment ("DME") company providing a wide range of ... Pennsylvania and Pittsburgh ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Bedford Laboratories™, a division of Ben Venue Laboratories, ... Topotecan Hydrochloride for Injection, 4 mg (base)/vial to ... the reference listed drug Hycamtin ® (topotecan ... Injection is indicated for the treatment of metastic ...
... Nektar Therapeutics (Nasdaq: NKTR ) will announce ... 2011 on Wednesday, April 27, 2011, after the close of ... will host a conference call to review the results beginning ... The press release and a live audio-only ...
Cached Medicine Technology:Bedford Laboratories™ to Begin Shipping Topotecan Hydrochloride for Injection, 4mg SD Vial 2Nektar to Announce Financial Results for the First Quarter of 2011 on Wednesday, April 27, 2011, After Close of U.S.-Based Financial Markets 2
(Date:4/16/2014)... According to a new study, endoscopists, recommendations for timing ... two small polyps are consistent with guideline recommendations in ... appropriate target for quality indicators. This is the first ... for timing of repeat colonoscopy after one to two ... patients. The study appears in the April issue of ...
(Date:4/15/2014)... CHAMPAIGN, Ill. Scientists have solved a decades-old medical mystery ... toxic way to fight invasive fungal infections, which kill about ... understand the mechanism of action of amphotericin, an antifungal drug ... even though it is nearly as toxic to human ... A report of the new findings appears in ...
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... that moderate to severe obstructive sleep apnea is independently ... death. , Results of the 20-year follow-up study show ... were four times more likely to die (hazard ratio ... a stroke (HR = 3.7), three times more likely ... times more likely to develop cancer. Results were adjusted ...
(Date:4/14/2014)... In a UT Dallas study involving serious youth offenders, the ... for the next seven years: "How long do you think ... the future encourages offending over time., Author Dr. Alex Piquero ... long life ahead of them offend at very high rates ... going to die much later in life offend much less., ...
Breaking Medicine News(10 mins):Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2
... foods in schools from September onwards - confectionery, crisps ... School Food trust. ,The trust, which was ... standards on food provided in schools – that includes ... to Dame Suzi Leather, the trust's chairwoman, New food ...
... was suffering from a crippling mosquito-borne virus disease the Chikungunya ... around this area//. The World Health Organization (WHO) said ... the Indian Ocean region. ,This disease has no ... the Reunion, Mauritius and Seychelles since January. The disease was ...
... said that mammograms were able to detect non progressive ... previous studies// show that 54% of the mammograms detect ... is about 1% only. But the present study is ... Sophia Zackrisson, a radiologist from the Epidemiological Research Group, ...
... Research Center of the Medical College of Wisconsin in Milwaukee found ... with the lowest BMI are at greatest risk of death from ... drivers risk of dying in a car crash. On the ... ,Researchers also found that obesity in women does not ...
... claimed that they have developed a vaccine against two ... question can easily kill humans and could potentially be ... viruses is that Hendra virus emerged in 1994, killing ... in Brisbane. Thereafter the trainer of Vo Rogue, died ...
... have been urged to produce more antibiotics by ... federal legislation// is being encouraged to provide drug ... ,Combating the drug-resistant microbes should deserve the utmost ... anti-biotics have so far been developed to treat ...
Cached Medicine News:Health News:Threat from Chikungunya, No Longer a Fear 2Health News:Mammograms Detect Non Progressive Cancer 2
... easy, breezy, beautiful image to its eyewear ... of stylish colors, trendy shapes, spring hinges, ... to target the broad demographics of the ... fashionable frames. The Cover Girl Eyewear collection ...
The license agreement for the manufacturing and distribution of Bulgari eyewear was signed by Luxottica Group in 1997.,Bulgari eyewear is designed for sleek, select people who want to distinguish the...
... The license agreement between Brook Brothers ... 1993. Characterized by lightweight materials and ... collections reflect the unique features of ... A product with classic style and ...
... debuted in 1937 with the Aviator style ... to Luxottica Group's brand portfolio in 1999. ... celebrities since day one, Ray-Bans styles are ... best-selling sunglasses in the world. Characterized by ...
Medicine Products: